Search

Your search keyword '"Xin, Shaojie"' showing total 266 results
Start Over Author "Xin, Shaojie"
266 results on '"Xin, Shaojie"'

51. Hepatitis B-related Acute-on-Chronic Liver Failure Induced by Hepatotropic Viral insult is Associated with Worse Prognosis Than that Induced by Non-Virus Insult

Author

Liang, Jing, primary, Liu, Lei, additional, Cao, Yingying, additional, Zhang, Qian, additional, Liu, Fang, additional, Yu, Chen, additional, Liu, Hua, additional, Duan, Zhongping, additional, Xu, Manman, additional, Xin, Shaojie, additional, You, Shaoli, additional, Song, Fangjiao, additional, Li, Jun, additional, and Han, Tao, additional

Published
2021
Full Text
View/download PDF

52. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF

Author

Li, Jiang, primary, Liang, Xi, additional, Jiang, Jing, additional, Yang, Lingling, additional, Xin, Jiaojiao, additional, Shi, Dongyan, additional, Lu, Yingyan, additional, Li, Jun, additional, Ren, Keke, additional, Hassan, Hozeifa Mohamed, additional, Zhang, Jianing, additional, Chen, Pengcheng, additional, Yao, Heng, additional, Li, Jiaqi, additional, Wu, Tianzhou, additional, Jin, Linfeng, additional, Ye, Ping, additional, Li, Tan, additional, Zhang, Huafen, additional, Sun, Suwan, additional, Guo, Beibei, additional, Zhou, Xingping, additional, Cai, Qun, additional, Chen, Jiaxian, additional, Xu, Xiaowei, additional, Huang, Jianrong, additional, Hao, Shaorui, additional, He, Jinqiu, additional, Xin, Shaojie, additional, Wang, Di, additional, Trebicka, Jonel, additional, and Chen, Xin, additional

Published
2021
Full Text
View/download PDF

56. Predictive Scores for Mortality in MAFLD-Related Acute-on-Chronic Liver Failure (MAFLD-ACLF): Development and Validation of MAFLD-MELD-Na and MAFLD-AARC Scores.

Author

Kumar, Ashish, Sarin, Shiv Kumar, Arora, Anil, Choudhury, Ashok, Arora, Vinod, Rela, Mohamed, Jothimani, Dinesh Kumar, Al Mahtab, Mamun, Devarbhavi, Harshad, Eapen, C.E., Goel, Ashish, Yaghi, Cesar, Ning, Qin, Chen, Tao, Jia, Jidong, Zhongping, Duan, Hamid, Saeed S., Butt, Amna Subhan, Wasim Jafri, Syed Muhammad, Shukla, Akash, Tan, Seok Siam, Kim, Dong Joon, Saraya, Anoop, Hu, Jinhua, Sood, Ajit, Goyal, Omesh, Midha, Vandana, Sahu, Manoj, Lee, Guan H., Treeprasertsuk, Sombat, Thanapirom, Kessarin, Mandot, Ameet, Maghade, Ravikiran, Lesmana, Laurentius A., Ghazinyan, Hasmik, Prasad, V.G.Mohan, Dokmeci, Abdulkadir, Sollano, Jose, Abbas, Zaigham, Shrestha, Ananta, Lau, George, Payawal, Diana, Shiha, Gamal, Duseja, Ajay K., Taneja, Sunil, Verma, Nipun, Rao, Padaki Nagaraja, Kulkarni, Anand, Karim, Fazal, Saraswat, Vivek Anand, Alam, Shahinul, Yokosuka, Osamu, Chowdhury, Debashis, Kedarisetty, Chandan Kumar, Saigal, Sanjiv, Sharma, Praveen, Prasad, Babita, Yattoo, Ghulam Nabi, Koshy, Abraham, Patwa, Ajay, Elbasiony, Mohamed, Rathi, Pravin, Maharshi, Sudhir, Dayal, V.M., Jha, Ashish, Kalista, Kemal, Gani, Rino A., Yuen, Man-Fung, Singh, Virendra, Singh, Ayaskanta, Violeta, Sargsyan, Huang, Chien-Hao, Mukewar, Saurabh, Xin, Shaojie, Rajaram, Ruveena, Panackel, Charles, Dadhich, Sunil, Sachdeva, Sanjeev, Behera, Sanatan, Kamani, Lubna, and Saithanyamurthi, Hemamala

Published
2023
Full Text
View/download PDF

67. PBMC transcriptomics identifies immune-metabolism disorder during the development of HBV-ACLF

Author

Li, Jiang, Liang, Xi, Jiang, Jing, Yang, Lingling, Xin, Jiaojiao, Shi, Dongyan, Lu, Yingyan, Li, Jun, Ren, Keke, Hassan, Hozeifa Mohamed, Zhang, Jianing, Chen, Pengcheng, Yao, Heng, Li, Jiaqi, Wu, Tianzhou, Jin, Linfeng, Ye, Ping, Li, Tan, Zhang, Huafen, Sun, Suwan, Guo, Beibei, Zhou, Xingping, Cai, Qun, Chen, Jiaxian, Xu, Xiaowei, Huang, Jianrong, Hao, Shaorui, He, Jinqiu, Xin, Shaojie, Wang, Di, Trebicka, Jonel, Chen, Xin, and Li, Jun

Abstract

ObjectiveHepatitis B virus-related acute-on-chronic liver failure (HBV-ACLF) pathophysiology remains unclear. This study aims to characterise the molecular basis of HBV-ACLF using transcriptomics.MethodsFour hundred subjects with HBV-ACLF, acute-on-chronic hepatic dysfunction (ACHD), liver cirrhosis (LC) or chronic hepatitis B (CHB) and normal controls (NC) from a prospective multicentre cohort were studied, and 65 subjects (ACLF, 20; ACHD, 10; LC, 10; CHB, 10; NC, 15) among them underwent mRNA sequencing using peripheral blood mononuclear cells (PBMCs).ResultsThe functional synergy analysis focusing on seven bioprocesses related to the PBMC response and the top 500 differentially expressed genes (DEGs) showed that viral processes were associated with all disease stages. Immune dysregulation, as the most prominent change and disorder triggered by HBV exacerbation, drove CHB or LC to ACHD and ACLF. Metabolic disruption was significant in ACHD and severe in ACLF. The analysis of 62 overlapping DEGs further linked the HBV-based immune-metabolism disorder to ACLF progression. The signatures of interferon-related, neutrophil-related and monocyte-related pathways related to the innate immune response were significantly upregulated. Signatures linked to the adaptive immune response were downregulated. Disruptions of lipid and fatty acid metabolism were observed during ACLF development. External validation of four DEGs underlying the aforementioned molecular mechanism in patients and experimental rats confirmed their specificity and potential as biomarkers for HBV-ACLF pathogenesis.ConclusionsThis study highlights immune-metabolism disorder triggered by HBV exacerbation as a potential mechanism of HBV-ACLF and may indicate a novel diagnostic and treatment target to reduce HBV-ACLF-related mortality.

Published
2022
Full Text
View/download PDF

68. Diagnosis and treatment of invasive fungal diseases in patients with severe liver diseases

Author

ZANG Hong and XIN Shaojie

Subjects
lcsh:Diseases of the digestive system. Gastroenterology, macromolecular substances, lcsh:RC799-869
Abstract

Invasive fungal diseases (IFDs) are an important factor affecting the prognosis of patients with severe liver diseases, and their early diagnosis remains a challenge for clinicians. The four most commonly seen IFDs are candidiasis, aspergillosis, cryptococcosis, and pneumocystis pneumonia. We should pay attention to the risk of developing IFDs in patients with severe liver diseases during clinical management. Particularly, early diagnosis and proper treatment of IFDs are important in high-risk patients. These are vital to improving the prognosis of patients with severe liver diseases.

Published
2016

70. FRI-161-Complication is a major risk factor for mortality of cirrhotic hepatitis B virus-related acuted-on-chronic liver failure patients: A multi-national study from Asian-pacific region

Author

Chen, Tao, primary, Yang, Zhongyuan, additional, Li, Jun, additional, Han, Tao, additional, Hu, Jinhua, additional, Xin, Shaojie, additional, Choudhury, Ashok, additional, Al-Mahtab, Mamun, additional, Nan, Yuemin, additional, Tan, Soek-Siam, additional, Hamid, Saeed Sadiq, additional, Subhan, Amna, additional, Jafri, Wasim, additional, Lee, Guan Huei, additional, Ghazinian, Hasmik, additional, Chawla, Yogesh, additional, Yuen, Man-Fung, additional, Jia, Ji-Dong, additional, Abbas, Zaigham, additional, Devarbhavi, Harshad, additional, Kadir Dokmeci, A., additional, Amarapurkar, Deepak, additional, Kumar, Manoj, additional, Lesmana, Laurentius A., additional, Lau, George, additional, Yokosuka, Osamu, additional, Duan, Zhongping, additional, Guo, Wei, additional, Ma, Ke, additional, Zhang, Zhongwei, additional, Sarin, Shiv Kumar, additional, and Ning, Qin, additional

Published
2019
Full Text
View/download PDF

71. Artificial Liver Treatment Improves Survival in Patients with Acute-on-Chronic Liver Failure

Author

Yang, Lingling, primary, Wu, Tianzhou, additional, Li, Jiang, additional, Xin, Jiaojiao, additional, Shi, Dongyan, additional, Jiang, Jing, additional, Liang, Xi, additional, Lu, Yingyan, additional, Yao, Heng, additional, Zhang, Huafen, additional, Sun, Suwan, additional, Li, Tan, additional, Hassan Mohamed, Hozeifa Mohamed, additional, Li, Jiaqi, additional, Ren, Keke, additional, Guo, Beibei, additional, Zhou, Xingping, additional, Chen, Jiaxian, additional, Hao, Shaorui, additional, Chen, Jiajia, additional, Xin, Shaojie, additional, Pan, Chen, additional, Han, Tao, additional, Chen, Yongping, additional, Lin, Shumei, additional, Duan, Zhongping, additional, Xu, Xiaowei, additional, Huang, Jianrong, additional, Chen, Xin, additional, Li, Lanjuan, additional, Li, Jun, additional, and Group, Chinese Group on the Study of Sever, additional

Published
2019
Full Text
View/download PDF

73. Comparison of extracorporeal cellular therapy (ELAD®) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure

Author

Duan,Zhongping, Xin,Shaojie, Zhang,Jing, You,Shaoli, Chen,Yu, Liu,Hongling, Zheng,Sujun, Li,Zheng, Ashley,Robert, Millis,Michael, Duan,Zhongping, Xin,Shaojie, Zhang,Jing, You,Shaoli, Chen,Yu, Liu,Hongling, Zheng,Sujun, Li,Zheng, Ashley,Robert, and Millis,Michael

Abstract

Zhongping Duan,1,* Shaojie Xin,2,* Jing Zhang,1 Shaoli You,2 Yu Chen,1 Hongling Liu,2 Sujun Zheng,1 Zheng Li,3 Robert Ashley,3 Michael Millis4 1Artificial Liver Center, Beijing You’an Hospital of Capital Medical University, Beijing, China; 2Department of Infectious Disease, Division III, 302 Military Hospital of China, Beijing, China; 3Research and Development, Vital Therapies, Inc, San Diego, CA, USA; 4Department of Surgery, University of Chicago, Chicago, IL, USA *These authors contributed equally to this work Background: Preliminary evidence of safety and efficacy of an extracorporeal cellular therapy (ELAD®) has been demonstrated in subjects with acute forms of liver failure. This study compared ELAD with standard of care in Chinese subjects with acute-on-chronic liver failure (ACLF), predominantly secondary to chronic viral hepatitis.Subjects and methods: Subjects meeting eligibility criteria were randomized to either the ELAD group or the control group. All subjects received plasma exchange and venovenous hemofiltration and either ELAD treatment for 3–5 days, unless terminated early, along with standard of care or standard of care alone (control) and were then followed up for 12 weeks.Results: Forty-nine subjects (ELAD subjects, 32; controls, 17) were randomized under this protocol. Kaplan–Meier analysis of transplant-free survival (TFS) revealed a significant difference in favor of ELAD vs control (P=0.049, Wilcoxon signed-rank test). There was a significant difference in TFS on day 28 in ELAD vs control (P=0.022). In a multiple regression model, the relationship between group assignment and outcome was significant (P=0.031) when changes in food intake and Model for End-Stage Liver Disease (MELD) scores at screening were included as additional independent variables. The duration of ELAD treatment alone was a significant predictor of TFS (P=0.043). Median time to a 5-point increase in MELD, transplant, or death was longer

Published
2018

74. Pregnane X receptor mediates sorafenib resistance in advanced hepatocellular carcinoma

Author

Feng, Fan, primary, Jiang, Qiyu, additional, Cao, Shuang, additional, Cao, Yu, additional, Li, Ruisheng, additional, Shen, Lijun, additional, Zhu, Hua, additional, Wang, Tao, additional, Sun, Lijun, additional, Liang, Erguang, additional, Sun, Huiwei, additional, Chai, Yantao, additional, Li, Xiaojuan, additional, Liu, Genyan, additional, Yang, Ruichang, additional, Yang, Zhi, additional, Yang, Yongping, additional, Xin, Shaojie, additional, and Li, Bo-an, additional

Published
2018
Full Text
View/download PDF

76. Preliminary Research of Off-Line Bioartificial Liver on Patients with Hbv Related Acute-On-Chronic Liver Failure

Author

Liu Hongling, Zang Hong, Rong Yihui, Mao Panyong, Zhu Bing, Xin Shaojie, Wan Zhihong, Liu Wanshu, and You Shaoli

Subjects
0301 basic medicine, medicine.medical_specialty, Liver tumor, Bilirubin, business.industry, Liver failure, Bioartificial liver device, medicine.disease, Gastroenterology, law.invention, 03 medical and health sciences, chemistry.chemical_compound, 030104 developmental biology, 0302 clinical medicine, chemistry, law, Internal medicine, medicine, 030211 gastroenterology & hepatology, Acute on chronic liver failure, business, Adverse effect, Survival rate, Off line
Abstract

Objective: The study aims to construct an off-line bioartificial liver support system (off-line BAL) with human liver cell line, and explore it’s safety and effect in patients suffering with HBV-related acute on chronic liver failure (ACLF). Methods: The off-line BAL was constructed with cultured HepG2 cell. Twenty patients with HBV-related ACLF were randomly separated into the two groups. Patients in the treatment group were dealt with plasma exchange (PE) first and then BAL treatment. The control group received a therapy of PE only . The clinical parameters were assessed at different times and survival rate was evaluated at 3 months. Results: In the treatment group, 9 patients’ general conditions and clinical symptoms were improved, total bilirubin decreased about 44.27%, MELD scores decreased to 21.71 from 24.26, prothrombin activity (PTA) increased to 48.97%, and there was a significant difference between pretreatment and post-treatment. Compared to the control group, PTA increased dramatically (51.02% vs. 37.24%; P=0.0477) at 4 weeks and MELD score decreasedsignificantly (21.71 vs. 24.47; P=0.0409) at post-treatment in BAL groups. During the 12 weeks, the survival rates were 70% and 50% (P=0.3613) in the treatment and control groups. No severe adverse events occurred and no liver tumor was found following three years of observation. Conclusions: The off-line BAL may be safe for patients with liver failure. It can improve the patients’ clinical conditions and laboratory parameters, but it has no obvious benefit compared to PE treatment. The routine clinical application still needs further evidence.

Published
2016

77. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure

Author

Wu, Tianzhou, primary, Li, Jiang, additional, Shao, Li, additional, Xin, Jiaojiao, additional, Jiang, Longyan, additional, Zhou, Qian, additional, Shi, Dongyan, additional, Jiang, Jing, additional, Sun, Suwan, additional, Jin, Linfeng, additional, Ye, Ping, additional, Yang, Lingling, additional, Lu, Yinyun, additional, Li, Tan, additional, Huang, Jianrong, additional, Xu, Xiaowei, additional, Chen, Jiajia, additional, Hao, Shaorui, additional, Chen, Yuemei, additional, Xin, Shaojie, additional, Gao, Zhiliang, additional, Duan, Zhongping, additional, Han, Tao, additional, Wang, Yuming, additional, Gan, Jianhe, additional, Feng, Tingting, additional, Pan, Chen, additional, Chen, Yongping, additional, Li, Hai, additional, Huang, Yan, additional, Xie, Qing, additional, Lin, Shumei, additional, Li, Lanjuan, additional, and Li, Jun, additional

Published
2017
Full Text
View/download PDF

78. Comparison of Detection Rate and Mutational Pattern of Drug-Resistant Mutations Between a Large Cohort of Genotype B and Genotype C Hepatitis B Virus-Infected Patients in North China

Author

Li, Xiaodong, primary, Liu, Yan, additional, Xin, Shaojie, additional, Ji, Dong, additional, You, Shaoli, additional, Hu, Jinhua, additional, Zhao, Jun, additional, Wu, Jingjing, additional, Liao, Hao, additional, Zhang, Xin-Xin, additional, and Xu, Dongping, additional

Published
2017
Full Text
View/download PDF

79. Comparison of extracorporeal cellular therapy (ELAD®) vs standard of care in a randomized controlled clinical trial in treating Chinese subjects with acute-on-chronic liver failure.

Author

Duan, Zhongping, Xin, Shaojie, Zhang, Jing, You, Shaoli, Chen, Yu, Liu, Hongling, Zheng, Sujun, Li, Zheng, Ashley, Robert, and Millis, Michael

Abstract

Background: Preliminary evidence of safety and efficacy of an extracorporeal cellular therapy (ELAD®) has been demonstrated in subjects with acute forms of liver failure. This study compared ELAD with standard of care in Chinese subjects with acute-on-chronic liver failure (ACLF), predominantly secondary to chronic viral hepatitis.Subjects and methods: Subjects meeting eligibility criteria were randomized to either the ELAD group or the control group. All subjects received plasma exchange and venovenous hemofiltration and either ELAD treatment for 3–5 days, unless terminated early, along with standard of care or standard of care alone (control) and were then followed up for 12 weeks.Results: Forty-nine subjects (ELAD subjects, 32; controls, 17) were randomized under this protocol. Kaplan–Meier analysis of transplant-free survival (TFS) revealed a significant difference in favor of ELAD vs control (P=0.049, Wilcoxon signed-rank test). There was a significant difference in TFS on day 28 in ELAD vs control (P=0.022). In a multiple regression model, the relationship between group assignment and outcome was significant (P=0.031) when changes in food intake and Model for End-Stage Liver Disease (MELD) scores at screening were included as additional independent variables. The duration of ELAD treatment alone was a significant predictor of TFS (P=0.043). Median time to a 5-point increase in MELD, transplant, or death was longer than 72 days with ELAD vs 26 days for control (P=0.036). Total bilirubin level decreased by 25% during ELAD treatment vs 37% increase in the control group (P [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

83. Combining Serum Cystatin C with Total Bilirubin Improves Short-Term Mortality Prediction in Patients with HBV-Related Acute-On-Chronic Liver Failure

Author

Wan, Zhihong, primary, Wu, Yichen, additional, Yi, Jing, additional, You, Shaoli, additional, Liu, Hongling, additional, Sun, Zhiqiang, additional, Zhu, Bing, additional, Zang, Hong, additional, Li, Chen, additional, Liu, Fangfang, additional, Li, Dongze, additional, Mao, Yuanli, additional, and Xin, Shaojie, additional

Published
2015
Full Text
View/download PDF

88. Analysis of Hepatitis B Virus Intrahepatic Covalently Closed Circular DNA and Serum Viral Markers in Treatment-Naive Patients with Acute and Chronic HBV Infection

Author

Li, Weijie, primary, Zhao, Jingmin, additional, Zou, Zhengsheng, additional, Liu, Yan, additional, Li, Baosen, additional, Sun, Ying, additional, Li, Xiaodong, additional, Liu, Shuhong, additional, Cai, Shaoping, additional, Yao, Weimin, additional, Xin, Shaojie, additional, Lu, Fengmin, additional, and Xu, Dongping, additional

Published
2014
Full Text
View/download PDF

90. Development of diagnostic criteria and a prognostic score for hepatitis B virus-related acute-on-chronic liver failure

Author

Wu, Tianzhou, Li, Jiang, Shao, Li, Xin, Jiaojiao, Jiang, Longyan, Zhou, Qian, Shi, Dongyan, Jiang, Jing, Sun, Suwan, Jin, Linfeng, Ye, Ping, Yang, Lingling, Lu, Yinyun, Li, Tan, Huang, Jianrong, Xu, Xiaowei, Chen, Jiajia, Hao, Shaorui, Chen, Yuemei, Xin, Shaojie, Gao, Zhiliang, Duan, Zhongping, Han, Tao, Wang, Yuming, Gan, Jianhe, Feng, Tingting, Pan, Chen, Chen, Yongping, Li, Hai, Huang, Yan, Xie, Qing, Lin, Shumei, Li, Lanjuan, and Li, Jun

Abstract

ObjectiveThe definition of acute-on-chronic liver failure (ACLF) based on cirrhosis, irrespective of aetiology, remains controversial. This study aimed to clarify the clinicopathological characteristics of patients with hepatitis B virus-related ACLF (HBV-ACLF) in a prospective study and develop new diagnostic criteria and a prognostic score for such patients.DesignThe clinical data from 1322 hospitalised patients with acute decompensation of cirrhosis or severe liver injury due to chronic hepatitis B (CHB) at 13 liver centres in China were used to develop new diagnostic and prognostic criteria.ResultsOf the patients assessed using the Chronic Liver Failure Consortium criteria with the exception of cirrhosis, 391 patients with ACLF were identified: 92 with non-cirrhotic HBV-ACLF, 271 with cirrhotic HBV-ACLF and 28 with ACLF with cirrhosis caused by non-HBV aetiologies (non-HBV-ACLF). The short-term (28/90 days) mortality of the patients with HBV-ACLF were significantly higher than those of the patients with non-HBV-ACLF. Total bilirubin (TB) ≥12 mg/dL and an international normalised ratio (INR) ≥1.5 was proposed as an additional diagnostic indicator of HBV-ACLF, and 19.3% of patients with an HBV aetiology were additionally diagnosed with ACLF. The new prognostic score (0.741×INR+0.523×HBV-SOFA+0.026×age+0.003×TB) for short-term mortality was superior to five other scores based on both discovery and external validation studies.ConclusionsRegardless of the presence of cirrhosis, patients with CHB, TB ≥12 mg/dL and INR ≥1.5 should be diagnosed with ACLF. The new criteria diagnosed nearly 20% more patients with an HBV aetiology with ACLF, thus increasing their opportunity to receive timely intensive management.

Published
2018
Full Text
View/download PDF

100. Association of hepatitis B virus mutations in basal core promoter and precore regions with severity of liver disease: an investigation of 793 Chinese patients with mild and severe chronic hepatitis B and acute-on-chronic liver failure

Author

Xu, Zhihui, primary, Ren, Xiaoqiang, additional, Liu, Yan, additional, Li, Xiaodong, additional, Bai, Siyu, additional, Zhong, Yanwei, additional, Wang, Lin, additional, Mao, Panyong, additional, Wang, Huifen, additional, Xin, Shaojie, additional, Wong, Vincent Wai-Sun, additional, Chan, Henry Lik-Yuen, additional, Zoulim, Fabien, additional, and Xu, Dongping, additional

Published
2010
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results